The results showed that high expression of ASRGL1 was significantly correlated with poor relapse-free survival (RFS), progression-free survival (PFS), disease-specific survival (DSS), and overall survival (OS) (p < 0.05, Figures 3A–D) in HCC, and with overall survival (OS), progression-free survival (PFS), and post-progression survival (PPS) in ovarian cancer (Figures 3L–N). Here, ASRGL1 is linked to ovarian carcinoma.